Farnsworth K, Farrell J, Fishman N,Freedman L, Gaman W, Gavin L, Gee D,Goldstein B, Hamad M, Harvey W, Hav-licek R, Herring C, Heuer M, Holloway R,Horowitz B, James D, Jost-Vu E, Kaplan R,Kawley A, Kennedy L, Kim K, Klaff L,Klein E, Klonoff D, Levinson L, LittlejohnT, McIlwain H, McInroy R, Miller J, MillerS, Mills R, Moretto T, Mudaliar S, MyersL, Norwood P, Osei K, Patel M, Patel N,Pullman J, Raad G, Radparvar A, Riff D,Rigby S, Robinson J, Rood R, RosenstockP, Saponaro J, Schmidt L, Shockey G,Schumacher D, Schwartz S, Shapiro J,Shapiro W, Snyder J, Sugimoto D, Sulli-van J, Taber L, Troupin B, Ward W, War-ren K, Weinstein R, Weiss D, Weiss R,Weissman P, Whitehouse F, Williams K,Wofford M, Wright D, Wysham C, YatesS, Zayed A, Zegarelli L, Zigrang W. Acknowledgments â€” This trial was supported by Amylin Pharma- ceuticals and Eli Lilly. The authors thank the Exenatide-113 Clin-